CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
Updated clinical & translational results: BOND-003 Cohort C- A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder ...
CG Oncology assumed with an Overweight at Morgan Stanley
Morgan Stanley assumed coverage of CG Oncology (CGON) with an Overweight rating and $55 price target Morgan Stanley sees a competitive profile ...
Yahoo Finance17d
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone ...